x54389DOTweeblyDOTcom / 617-open-letter-to-ftc-re-the-street-inc-possible-nationwide-advertising-fraud-and-deceptionDOThtml
this is the first person who works at MD Anderson to like Isoray on FB
so yes this is a big deal
have you been following this company? All they have ever done is release good news and look what happens afterwards. Like i said before this is clearly manipulation and Babcock & company needs to stick to their guns when the LOWBALL offers start rolling in because thats what this is leading to
Transaction Date Insider Name Title Buy/Sell Number of Shares Average Share Price Total Transaction Actions
6/9/2015 Dwight William Babcock CEO Buy 10,000 $1.53 $15,300.00
GO. Growth Operators.
We believe growth is the lifeblood of every company. Our team of operating executives delivers comprehensive and disciplined solutions, which fully integrate consumer insights, product, marketing, sales and operations, to achieve a competitive advantage, ultimately delivering superior financial performance. We bring diverse industry experiences from world-class global brands in aviation, automotive, communications, healthcare and sporting goods.
This guy is going to help expand this company to where it needs to be
shorts are screwed
WRONG stop posting misinformation
its not 20 million shares its $20 million the whole point of a shelf offering is the amount of shares can be any amount. Isoray could offer 4 million shares at $5
I mention his name and yahoo deletes my posts so i wont use his name but we all know what he did
Dwight William Babcock, IsoRay's CEO and a director of the company, recently acquired 10,000 shares of the company. The buys took place at prices ranging from $1.52 to $1.53 per share, on June 09, 2015. Babcock now owns 301,402 shares of the company. Babcock operates out of Tucson, AZ.
looks like they are only defending against the lawsuit hopefully they file one against AF & Thestreet after this one is thrown out
Steven Johnson, M.D.
David Saunders, M.D.
Archbold Memorial Hospital
Lewis Hall Singletary Oncology Center
919 South Broad Street
Thomasville, GA 31792
This protocol was designed and developed by the Archbold Memorial Hospital at Lewis Hall Singletary Oncology Center. It is intended to be used only in conjunction with institution-specific IRB approval for study entry. No other use or reproduction is authorized by Lewis Hall Singletary Oncology Center nor does Lewis Hall Singletary Oncology Center assume any responsibility for unauthorized use of this protocol.